[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad Autonoma de Nuevo Leon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":266},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,71,96,118,142,163,185,214,245],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100582297","phase-2-ppis-and-in-hospital-morbidity-in-acute-variceal-bleeding-with-chronic-liver-disease-100582297",false,"NCT06861478","PPIs and In-Hospital Morbidity in Acute Variceal Bleeding With Chronic Liver Disease","In-Hospital Morbidity Associated With Proton Pump Inhibitors in Acute Variceal Bleeding and Chronic Liver Disease Treatment","Liver-IMPACT","Inclusion Criteria\n\n* Adult\n* Cirrhosis\n* Variceal Bleeding with only endoscopic findings consistent with portal hypertension complications\n* Hypovolemic shock and Variceal bleeding\n\nExclusion Criteria:\n\n* Shock of any type other than hypovolemic.\n* No cirrhotic patients\n* Patients that have severe Hepatic Encephalopathy at admission (West Haven 3 and 4)\n* Hepatorenal syndrome\n* Acute on chronic with CLIF-C \\>50 points\n* Septic patients\n* Spontaneous Bacterial Peritonitis\n\nElimination Criteria\n\n* Voluntary removal of the study\n* Violation of the study protocol\n* Patients in the no PBI group that need prolonged mecánica ventilación.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","With this study, the investigators pretend to describe intrahospital morbidity in patients living with cirrhosis (PLC) who present to the emergency department with variceal bleeding (VB).\n\nThis study is a longitudinal, prospective, experimental, analytical single-center clinical trial. The study will be performed in the Hospital Universitario \"Jose E. González\" de la Factultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.\n\nThe studied population consists of adult-age patients with previous, recent, or new diagnoses of cirrhosis who present to the ED with VH without shock, infection, or acute or chronic disease with a \\\u003C30% probability of death (CLIF-C \\\u003C50). The exclusion criteria involve minor age, Acute Liver Failure (ALF), ICU patients, Hepatorenal Syndrome, sepsis or infection, and shock on admission except for hypovolemic and CLIF-C \\>50 points. Elimination criteria involve patients who want to discontinue treatment and patients with confounding endoscopic findings (Erosive esophagitis, peptic ulcers, duodenal ulcers, bleeding GAVE, and atrophic gastritis).\n\nAfter the endoscopic intervention, the investigators will propose inclusion. After acceptance with Informed Consent, the investigators will randomize the patients to receive or not receive Omeprazole\u002F Pantoprazole 40 mg IV per day until discharge. The primary outcome will represent several morbidity situations in these patients, including Hepatic Encephalopathy grades III and IV, intra-hospital infections, re-bleeding, shock, and acute kidney failure.\n\nThe secondary outcomes include the individual analysis of each component of our compound primary outcome, mortality by day 30, differences when grouping patients by Child-Pugh stratification, and comparing results in patients receiving omeprazole for more or less than 5 days.",[27],"Morbidity",[29,27,30],"Variceal Bleeding","Proton Pump Inhibitors","RECRUITING","2026-06-10",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":35},"2024-10-20",{"date":39,"type":21},"2026-09-20",{"name":41,"class":42},"Universidad Autonoma de Nuevo Leon","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100636872","upper-punctal-plug-occlusion-in-previous-lower-punctal-occlusion-100636872","NCT07571330","Upper Punctal Plug Occlusion in Previous Lower Punctal Occlusion.","Effectiveness of Upper Punctal Plug Occlusion in Patients With Dry Eye Disease With Previous Lower Punctal Occlusion.","Inclusion Criteria:\n\n* Patients of both sexes\n* One or both eyes may be included\n* Inferior lacrimal punctum occluded (with a punctal plug or cauterization), clinically sealed under slit-lamp examination\n* Functional superior lacrimal punctum\n* Aqueous-deficient dry eye (such as Sjögren's disease, graft-versus-host disease, or primary dry eye disease.)\n* Age \\>18 years\n* OSDI score \\>13 and one of the following signs: Tear film markers (Fluorescein tear break up-time \\\u003C5, First non-invasive tear breakup time \\\u003C10, Schirmer test without anesthesia \\\u003C10 mm, Schirmer test with anesthesia \\\u003C10 mm), Ocular surface markers (corneal staining \\>5 spots or conjunctival staining \\>9 spots).\n\nExclusion Criteria:\n\n* Active ocular surface infection.\n* Patients who are unwilling to participate or to provide written informed consent.",{"count":52,"type":21},36,[54],"NA","This study evaluates the therapeutic effect of upper punctal plug occlusion in patients with dry eye disease with previous lower punctal occlusion.",[57,58],"DED","Aqueous-deficient Dry Eye Disease",[60,57,61,62],"Aqueous-deficient dry eye disease","Punctual plug","Superior punctual plug","2026-05-04",{"date":65,"type":35},"2026-05-06",{"date":67,"type":35},"2026-02-12",{"date":69,"type":21},"2026-11-01",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100627466","losartan-for-corneal-fibrosis-100627466","NCT07449000","Losartan for Corneal Fibrosis","Topical Losartan as Treatment to Reduce Corneal Scarring Fibrosis","* Inclusion Criteria:\n\n  * Adults aged 18 years or older\n  * Presence of corneal scar with a duration of at least 1 month\n  * Corneal scars of any etiology\n  * Corneal scars with or without corneal neovascularization\n  * Stable corneal scar without epithelial defect\n  * No active treatment for the underlying condition for at least 1 month\n* Exclusion Criteria:\n\n  * Refusal or inability to provide written informed consent\n  * Presence of corneal epithelial defect or friable epithelium\n  * Age under 18 years\n  * Pregnancy\n  * Known allergy or hypersensitivity to losartan",{"count":79,"type":21},46,[54],"This is a prospective, randomized, double-blinded, controlled clinical trial designed to evaluate the efficacy and safety of topical losartan in improving visual acuity, contrast sensitivity and reducing corneal densitometry, corneal aberrations and corneal scarring severity in adult patients with corneal scars of different etiologies. Participants will be randomly assigned to receive either topical losartan 0.8 mg\u002FmL or placebo eyedrops 6 times per day for six months.",[83],"Corneal Scarring Fibrosis",[85,86,87,88,89],"Corneal scar","Corneal scarring","Corneal haze","Corneal opacity","Topical losartan",{"date":91,"type":35},"2026-05-08",{"date":67,"type":35},{"date":94,"type":21},"2027-03-01",{"name":41,"class":42},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":43},"100408927","autologous-platelet-rich-plasma-aprp-in-the-treatment-of-neurotrophic-keratopathy-100408927","NCT04604834","Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy","Inclusion Criteria:\n\n* Patients with:\n\n  * Neurotrophic keratopathy diagnosed by esthesiometry (defined as central corneal sensitivity ≤ 3cm using Cochet-Bonnet aesthesiometer).\n  * Corneal erosions.\n  * Neurotrophic keratopathy secondary to: diabetes mellitus, herpetic keratitis, microbial keratitis sequelae (bacteria, Acanthamoeba, fungi, herpes), limbal stem cell deficiency, chemical or thermic burn sequelae at least 3 months after the accident, ocular trauma with penetrating wound fixed at least 3 months before the trial, surgery carried out at least 3 month before the trial (including keratoplasty, laser in situ keratomileusis, phacoemulsification cataract surgery, extracapsular cataract extraction), adenoviral keratoconjunctivitis resolved at least 3 months the trial.\n\nExclusion Criteria:\n\n* Patients diagnosed with:\n\n  * Other ocular surface pathology presenting with corneal erosions but without corneal hyposensitivity.\n  * Corneal epithelial defect with or without corneal hyposensitivity.\n* Pregnant women, homeless, migrants.",{"count":103,"type":21},39,[54],"Neurotrophic keratopathy (NK) is a condition where the cornea loses its capacity to feel pain and touch. This causes a decrease in the production of certain substances that maintain the integrity of the corneal epithelium (the most superficial layer that covers the cornea). As a result, the cornea cannot heal wounds as fast as it should and this could lead to corneal breakdown. This disease is chronic, meaning that it does not resolve quickly, and the treatments commonly used to manage it (such as artificial tears) take a long time to work, which makes it hard to follow doctor's orders. Autologous platelet-rich plasma is a substance that is obtained from the patient's own blood and it may contain those components that are missing in the tears of people with NK. The purpose of this experiment is to find out whether APRP+PFAT is better than APRP alone or PFAT alone in the treatment of NK. Participants will be randomly assigned to one of three groups: one group will start with APRP, other will start with PFAT and another with PFAT+APRP. The participants will receive each treatment for four weeks, and then the subjects will switch groups and use them for four weeks each (12 weeks total). Investigators will evaluate different parameters that will let us know if your condition is improving. These evaluations will be carried out every four weeks from the start to the end of the protocol. In case of intolerance or adverse effects, treatment will be discontinued.",[107],"Neurotrophic Keratopathy",[109,110,111],"Autologous PRP","Neurotrophic keratopathy","Autologous platelet-rich plasma",{"date":65,"type":35},{"date":114,"type":35},"2020-11-01",{"date":116,"type":21},"2027-12-01",{"name":41,"class":42},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":43},"100344658","efficacy-and-safety-of-thermic-devices-in-the-treatment-of-meibomian-gland-dysfunction-100344658","NCT03767530","Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction","Inclusion Criteria:\n\n* Patients diagnosed with:\n\n  * Dry eye syndrome with meibomian gland dysfunction alone or in combination of other type of dry eye.\n  * Patients who were previously treated with eyelid massages and warm compresses without any improvement.\n\nExclusion Criteria:\n\n* Pregnant women.\n* History of ocular surgery within three months prior to inclusion.\n* History of trauma, infection or inflammation within three months prior to inclusion.\n* Contact lens use in the last week before inclusion.\n* Patients with active ocular allergic disease.\n* Patient with microbial keratitis.",{"count":125,"type":21},42,[54],"Dry eye syndrome is a common eye disease that affects 1 to 2 out of 10 persons around the planet. One common cause of this disease is the meibomian gland dysfunction. Meibomian glands are very small glands located at the rim of the eyelids that produce an oily substance that prevents the evaporation of tears. When these glands are compromised, the tear film evaporates quickly and the eyes dry up. This disease presents as eye irritation, foreign body sensation, inflammation, etc. The treatment of choice for MGD is eyelid massage and warm compresses 2 times a day. However, these treatments not always work perfectly, and as a result, patients find it hard to follow doctor's orders. Another kind of treatment is thermal therapy. There are several devices that are designed to apply heat on the eyelids, such as Lipiflow, MiBo Thermoflo, and Blephasteam. In this study, we want to find out whether thermal therapy with MiBo Thermoflo works better than warm compresses and eyelid massage use in the treatment of dry eye caused by MGD. To do this, we will select several patients and will assign them randomly to either the group with thermal therapy with MiBo Thermoflo or to the group with warm compresses and eyelid massage. The Mibo group will receive 3 sessions of thermal therapy at 2 weeks interval and the control group warm compresses and eyelid massage 2 times per day. All subjects will have a follow up of 24 weeks and we will compare results for both groups at the end of the study.",[129],"Meibomian Gland Dysfunction",[131,132,133,134,135],"Meibomian gland dysfunction","Mibo","MGD","Dry eye disease","Thermic devices",{"date":91,"type":35},{"date":138,"type":35},"2019-09-01",{"date":140,"type":21},"2027-12-20",{"name":41,"class":42},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":43},"100335917","autologous-platelet-rich-plasma-in-the-treatment-of-persistent-epithelial-defects-100335917","NCT03653650","Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects","Autologous Platelet-rich Plasma in the Treatment of Persistent Corneal Epithelial Defects","Inclusion Criteria:\n\n* Patients with persistent epithelial defect and at least one of the following diagnoses:\n\n  * Recurrent corneal epithelial defect.\n  * Neurotrophic corneal ulcer.\n  * Neurotrophic keratopathy secondary to any disease (i.e. diabetes mellitus, infection with herpes simplex virus or herpes zoster virus, microbial keratitis sequelae, multiple sclerosis, Parkinson's disease, VII cranial nerve palsy, chemical or thermic burn sequelae, trauma, surgery, iatrogenic, chronic dry eye, rheumatic disease).\n\nExclusion Criteria:\n\n* Patients diagnosed with:\n\n  * Peripheral ulcerative keratitis, or Mooren's ulcer.\n  * Active infectious keratitis and\u002For ulcers.",{"count":150,"type":21},54,[54],"Persistent epithelial defects (PED) are corneal ulcers that do not heal within the first two weeks of treatment with artificial tears or ocular lubricant ointment. It is believed that this condition is the result of the loss of certain substances normally present in the tears that aid in the healing process of the cornea. When the eye is healthy, these ulcers typically heal rapidly. However, when there is an underlying disease such as diabetes, this healing process is altered and it takes longer for the ulcer to heal. Autologous platelet-rich plasma (PRP) is a substance that is obtained from the patient's own blood and it is believed this substance may replace those missing factors in the tears of patients with PED. The purpose of this investigation is to find out whether PRP combined with a bandage contact lens is better than preservative free lubricant combined with bandage contact lens or than eye patch with ocular lubricant ointment for the treatment of PED. Participants will be randomly assigned to one of the three groups and will get the treatment until the ulcer heals completely. We will count the days it takes for the PED to heal and based on that we will determine wich treatment is more effective (the treatment that takes the least days to heal will be considered the most effective). Since this disease is difficult to treat and doesn't have a gold standard treatment, usually the available treatments are not as good as we would like, therefore, the ulcer might progress even to perforation regardless of the treatment. In these cases, we will provide appropriate treatment for progressive corneal thinning and corneal perforation.",[154],"Persistent Epithelial Defect",[156,154],"Platelet-Rich Plasma",{"date":65,"type":35},{"date":159,"type":35},"2018-08-30",{"date":161,"type":21},"2027-08-01",{"name":41,"class":42},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":43},"100336091","binocular-visual-therapy-and-video-games-for-amblyopia-treatment-100336091","NCT03655912","Binocular Visual Therapy and Video Games for Amblyopia Treatment.","Inclusion Criteria:\n\n* Patients with anisometropic amblyopia, strabismic amblyopia or both\n* Patients with out previous amblyopia treatment\n* Patient with previous strabismus surgery or use of there best corrected visual acuity glasses for at least 1 month\n* Birth at term gestational age\n* Without any systemic or ophthalmic comorbidities\n* Previous patients parent verbal and fiscal assessment.\n\nExclusion Criteria:\n\n* Any other amblyopia diagnosis (deprivation)\n* Any previous amblyopia treatment\n* Any previous intraocular surgery\n* Any ocular condition\n* Any neurologic conditions or psychomotor development alterations\n* Patients not able to cooperate for visual acuity or stereopsis evaluation","4 Years","10 Years",{"count":20,"type":21},[54],"Amblyopia, or lazy eye, is best defined by the American Academy of Ophthalmology as a unilateral or bilateral reduction of the best corrected visual acuity that occurs in the setting of an otherwise normal eye, or a structural abnormality involving the eye or visual pathway with reduction in visual acuity that cannot be attributed only to the effect of the structural abnormality. Which causes an abnormal visual experience early in life, with consequences such as deficiencies in the ability to perceive contrast and\u002For movement, visual acuity, accommodation and stereopsis. The treatment of choice consists in patching of the fellow eye 2 hours per day. The disadvantage of this treatment modality is that patients end up not complying and when treatment is interrupted, lazy eye reappears. Amblyopia was thought to be a monocular disease, now a days there are reports of cortical visual paths changes in both eyes (the fellow and amblyopia eye), believing that it might be a monocular consequence of a binocular disease. Following that statement new treatment studies have arisen, stimulating both eyes not only to improve visual acuity in the lazy eye, but to restore binocular function as well. These treatments use videogames in celular phones, computers, or tablets where the fellow eye is exposed to reduced contrast and the lazy eye is exposed to full-contrast. Although the evidence is promising, more studies are needed to establish effectivity and security of this treatment modality.",[175],"Amblyopia",[175,177,178],"Binocular therapy","Videogames",{"date":65,"type":35},{"date":181,"type":35},"2018-10-09",{"date":183,"type":21},"2026-12",{"name":41,"class":42},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":43},"100631198","anti-inflammatory-effects-of-pecan-nut-oil-supplementation-in-adults-with-overweight-a-randomized-controlled-parallel-group-clinical-trial-100631198","NCT07497555","Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial","Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Non-Randomized Controlled Parallel-Group Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* Body mass index (BMI) ≥25 and \\\u003C30 kg\u002Fm² (overweight)\n* Willingness to participate and provide written informed consent\n* Ability to comply with study procedures and attend scheduled visits\n* Stable dietary habits and physical activity levels during the study period\n\nExclusion Criteria:\n\n* Diagnosis of chronic diseases such as diabetes mellitus, cardiovascular disease, liver disease, renal disease, or autoimmune disorders\n* Use of anti-inflammatory medications, lipid-lowering drugs, or dietary supplements within the last 3 months\n* Smoking or excessive alcohol consumption\n* Pregnancy or lactation\n* Known allergy or intolerance to nuts or nut-derived products\n* Participation in another clinical trial within the last 3 months\n* Any condition that, in the investigator's opinion, may interfere with study participation or outcomes",true,"55 Years",{"count":195,"type":21},50,[54],"The goal of this clinical trial is to evaluate whether daily supplementation with cold-pressed pecan nut oil can reduce inflammation in adults with overweight. The main questions it aims to answer are:\n\nDoes pecan nut oil supplementation reduce inflammatory biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α)? Does pecan nut oil supplementation improve biochemical parameters such as fasting blood glucose and lipid profile? Researchers will compare an experimental group receiving pecan nut oil to a control group with no intervention to determine its effect on inflammation and metabolic parameters.\n\nParticipants will:\n\nConsume 30 g\u002Fday of cold-pressed pecan nut oil under fasting conditions for 8 weeks (experimental group) Maintain their usual diet and physical activity throughout the study Attend two evaluation visits (baseline and Day 60) for blood sample collection and anthropometric measurements Provide dietary information using a 24-hour dietary recall",[199],"Overweight (BMI > 25)",[201,202,203,204,205],"pecan nut oil","overweight","controlled trial","nutraceuticals","chronic low-grade inflammation","2026-03-23",{"date":208,"type":35},"2026-03-27",{"date":210,"type":35},"2025-10-15",{"date":212,"type":21},"2026-07-30",{"name":41,"class":42},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":17,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":230,"overallStatus":236,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":43},"100579486","educational-intervention-be-yourself-digital-innovation-to-prevent-teenage-pregnancy-100579486","NCT06824922","\"Educational Intervention 'Be Yourself': Digital Innovation to Prevent Teenage Pregnancy\"","Be Yourself\" Educational Intervention With Web Page and Chatbot to Promote Self-determined Motivation and Prevent Teenage Pregnancy: Pilot Trial.","BYE-Chat","Inclusion Criteria:\n\n* Adolescents between 11 and 15 years of age enrolled in public high schools in Nuevo León will be included.\n\npublic high schools in Nuevo León.\n\n* Be male or female, regardless of whether they have initiated their sexual life. sexually active.\n* Have access to a computer room with internet to use the web page and the interventions chatbot.\n\nthe interventions chatbot.\n\n* Live at the same address with their parents or legal guardian.\n\nExclusion Criteria:\n\n* Have previously participated in a similar sexuality intervention.\n* Have cognitive or developmental difficulties that impede their understanding of the intervention and use of the technology platform, including people with\n* Autism Spectrum Disorder (ASD) at levels that affect functional communication, Attention Deficit Hyperactivity Disorder (ADHD) with severe attention difficulties, or those who cannot read and write.","11 Years","15 Years",{"count":225,"type":21},150,[54],"Introduction: Adolescent pregnancy and early initiation of sexual activity is a serious global public health problem, every year, around sixteen million adolescents between 15 and 19 years of age give birth, representing 11% of all births globally. Objective: To design a protocol of a pilot Randomized Controlled Trial to evaluate the preliminary efficacy of the \"Be Yourself\" intervention to increase self-determined motivation to prevent pregnancy in adolescents in secondary education. Methods: The protocol was developed based on the Protocol Items: ecommendations for Interventional Trials 2013 (SPIRIT2013) Statement, in the City of Monterrey, Nuevo León, Mexico in 2023. Results: The protocol outlined the design of the intervention, structured the content of the sessions using a logic model of intervention, and developed manuals for program facilitators and guides for participants. In addition, a website and a chatbot with Artificial Intelligence were developed, and the strategy for the application of the evaluation instruments was established. Conclusion: The educational intervention \"Be yourself\" is projected as a promising program to promote self-determined motivation and prevent adolescent pregnancy.",[229],"Prevenir el Embarazo Adolescente",[231,232,233,234,235],"Self-determination","Teenage Pregnancy","Sexual behaviour","Prevention","Randomized controlled trial","NOT_YET_RECRUITING","2025-02-08",{"date":239,"type":35},"2025-02-13",{"date":241,"type":21},"2025-02-06",{"date":243,"type":21},"2025-06-06",{"name":41,"class":42},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":251,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":43},"100559490","clinical-trial-on-the-efficacy-of-intralesional-triamcinolone-versus-candida-albicans-antigen-in-treating-alopecia-areata-100559490","NCT06564805","Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata","Inclusion Criteria:\n\n* Diagnosis of alopecia areata\n* SALT score of less than 50% extension\n* Has not received any topical or systemic treatment in the last month\n* Signed informed consent\n\nExclusion Criteria:\n\n* Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features\n* Pregnancy or breast-feeding\n* Patients in medications that could cause hair loss as side-effects","6 Years",{"count":253,"type":21},30,[54],"The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.",[257],"Alopecia Areata","2024-08-19",{"date":260,"type":35},"2024-08-21",{"date":262,"type":35},"2024-08-20",{"date":264,"type":21},"2025-12-31",{"name":41,"class":42},""]